|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 233.69 USD | -1.68% |
|
-3.26% | +3.67% |
| Jan. 16 | Promising launch for Wegovy pill: Novo Nordisk shares surge in the US | |
| Jan. 16 | Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly | RE |
Company Valuation: Iqvia Holdings Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 34,352 | 53,900 | 38,056 | 42,227 | 35,667 | 39,797 | 39,797 | - |
| Change | - | 56.91% | -29.39% | 10.96% | -15.54% | 11.58% | 0% | - |
| Enterprise Value (EV) 1 | 44,983 | 64,659 | 49,587 | 54,524 | 47,948 | 53,144 | 52,607 | 51,532 |
| Change | - | 43.74% | -23.31% | 9.96% | -12.06% | 10.84% | -1.01% | -2.04% |
| P/E ratio | 125x | 57x | 35.8x | 31.7x | 26.2x | 32.9x | 27.4x | 23.5x |
| PBR | 5.71x | 9.11x | 6.6x | 7.05x | 5.94x | 6.27x | 5.37x | 4.54x |
| PEG | - | 0x | 2.3x | 1.2x | 9.55x | -6.34x | 1.4x | 1.4x |
| Capitalization / Revenue | 3.02x | 3.88x | 2.64x | 2.82x | 2.32x | 2.46x | 2.33x | 2.21x |
| EV / Revenue | 3.96x | 4.66x | 3.44x | 3.64x | 3.11x | 3.28x | 3.08x | 2.86x |
| EV / EBITDA | 18.9x | 21.4x | 14.8x | 15.3x | 13x | 14.1x | 13.1x | 12.1x |
| EV / EBIT | 22.2x | 25x | 17.8x | 17.9x | 15.5x | 22.8x | 20.2x | 18.1x |
| EV / FCF | 33.5x | 28.1x | 31.3x | 36.3x | 22.7x | 26.2x | 23.8x | 22.1x |
| FCF Yield | 2.99% | 3.56% | 3.2% | 2.75% | 4.41% | 3.82% | 4.2% | 4.53% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.43 | 4.95 | 5.72 | 7.29 | 7.49 | 7.101 | 8.521 | 9.951 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 11,359 | 13,874 | 14,410 | 14,984 | 15,405 | 16,186 | 17,076 | 18,047 |
| EBITDA 1 | 2,384 | 3,022 | 3,346 | 3,569 | 3,684 | 3,781 | 4,010 | 4,265 |
| EBIT 1 | 2,030 | 2,591 | 2,779 | 3,050 | 3,100 | 2,332 | 2,602 | 2,852 |
| Net income 1 | 279 | 966 | 1,091 | 1,358 | 1,373 | 1,235 | 1,450 | 1,670 |
| Net Debt 1 | 10,631 | 10,759 | 11,531 | 12,297 | 12,281 | 13,346 | 12,809 | 11,734 |
| Reference price 2 | 179.17 | 282.14 | 204.89 | 231.38 | 196.51 | 233.69 | 233.69 | 233.69 |
| Nbr of stocks (in thousands) | 191,726 | 191,040 | 185,740 | 182,500 | 181,500 | 170,300 | 170,300 | - |
| Announcement Date | 2/10/21 | 2/15/22 | 2/10/23 | 2/14/24 | 2/6/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 33.47x | 3.33x | 14.23x | -.--% | 40.48B | ||
| 37.96x | 5.53x | 18.52x | 0.9% | 48.12B | ||
| 103.47x | 6.63x | 66.61x | -.--% | 37.42B | ||
| 54.52x | 11.18x | 31.09x | 0.35% | 30.68B | ||
| -21.53x | 6248.57x | -20.41x | -.--% | 23.25B | ||
| 41.27x | 6.69x | 30.41x | -.--% | 17.21B | ||
| 27.63x | 2.23x | 9.97x | 0.88% | 14.79B | ||
| Average | 39.54x | 897.74x | 21.49x | 0.3% | 30.28B | |
| Weighted average by Cap. | 44.09x | 690.90x | 24.11x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- IQV Stock
- Valuation Iqvia Holdings Inc.
Select your edition
All financial news and data tailored to specific country editions
















